Tests BEY2153 in people with early Alzheimer's disease
Tests BEY2153 pills against placebo in adults with early Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
Key facts
- Where
- Seoul, South KoreaSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 85 years old?
Source: NCT06885567, who can take part
Where in South Korea
- Severance hospitalSeoul, South KoreaNo longer taking part
- SMG-SNU Boramae Medical CenterSeoul, South KoreaNo longer taking part
- Yeouido St. Mary's HospitalSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BeyondBio Inc.
- Trial code
- NCT06885567
- Record updated
- 20 March 2025
- Original description
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Parallel Design, Placebo-controlled, Phase 2 Clinical Trial and Open-Label Extension Study to Evaluate the Safety and Efficacy for BEY2153 in Patients with Early Alzheimer's Disease
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.
Inclusion: Male and female adults at the age of ≥ 55 to ≤ 85 at the time of informed consent; Patients diagnosed according to the NIA-AA 2024 Criteria for Diagnosis with Mild Cognitive Impairment (MCI) or diagnosed with mild Alzheimer's disease; CDR-GS 0.5-1.0 at Screening; MMSE ≥ 20 at Screening; Amyloid-positive at amyloid PET scan; Patients who are capable of understanding information provided and can voluntarily sign written informed consent form; Patients who completed the 26-week visit in the Main Study; Patients who provided written consent to participate in the Extension Study.
Exclusion: Patients with active bacterial infections who have received antibiotics within 7 days prior to Screening; Patients with a history of hypersensitivities to any of the components of investigational product; Patients who have been hospitalized or treated for suicidal behavior within 5 years prior to Screening or whose C-SSRS results at Screening indicate serious suicidal ideation or behavior; Patients who have received treatment for Alzheimer's disease (e.g., Lecanemab) within 6 months prior to Screening; Women who test positive for pregnancy at Screening, or women and men of childbearing potential who are planning to become pregnant, or who do not agree to use adequate contraception* during the study and for 4 weeks after the end of study drug administration; *Adequate contraception: complete abstinence, hormonal contraceptives with no known drug interactions [Levonorgestrel intrauterine system (IUS) (Mirena), Medroxyprogesterone], surgical sterilization (including vasectomy, bilateral salpingectomy and ligation). However, intermittent abstinence (e.g., using ovulation timing, symptothermal method, or post-ovulation) or external ejaculation are not considered adequate contraception; Patients treated with other IP within 4 weeks prior to screening; Subjects diagnosed with cognitive impairment due to causes other than substrate causes such as brain lesions, psychiatric disorders, or Alzheimer's disease (e.g., stroke, Parkinson's disease, Lewy body disease, vascular dementia); Subjects with any of the following cardiovascular diseases at Screening; Cerebrovascular disease within the past 6 months (cerebral infarction, cerebral hemorrhage, transient ischemic attack, etc.); Myocardial infarction or unstable angina pectoris within the past 6 months; New York Heart Association (NYHA) Class II congestive heart failure; QTcF ≥450 msec or clinically significant electrocardiogram (ECG) abnormalities; Patients with malignant tumors; Patients with medical conditions that can affect cognitive decline such as hypothyroidism, vitamin B12 or folate deficiency, niacin deficiency, etc; Patients with a history of alcohol related disorders within the past 6 months; Patients with a positive HIV antibody test result at Screening; Patients with a positive HBs antigen or HCV antibody test at Screening; Patients expected to require the administration of a long-acting benzodiazepine (BDZ) for the treatment of sleep disorders at Screening; Any of the following laboratory test values at Screening:; Serum Creatinine >1.5×ULN or eGFR (MDRD) <40 mL/min/1.73 m2; Any of the following: AST, ALT >3×ULN, or Total bilirubin >2xULN; Any of the following laboratory test values at Baseline:; Serum Creatinine >1.5×ULN or eGFR (MDRD) <40 mL/min/1.73 m2; Any of the following: AST, ALT >3×ULN, or Total bilirubin >2xULN; Pregnant or lactating women or women who are tested positive for pregnancy at Screening; Patients who are considered ineligible for study participation for other reasons based on the judgment of the investigator; [Extension Study]; Subjects who have dropped out of the Main Study; Patients who, in the investigator's judgement, are not suitable for participation in Extension Study.